Agostinetto E - Search Results

1

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models.

Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, Di Rosa F, Andrade R, Invernizzi P. Gerussi A, et al. Among authors: agostinetto e. Int J Mol Sci. 2021 Apr 27;22(9):4557. doi: 10.3390/ijms22094557. Int J Mol Sci. 2021. PMID: 33925355 Free PMC article. Review.

2

Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.

Cau R, Solinas C, De Silva P, Lambertini M, Agostinetto E, Scartozzi M, Montisci R, Pontone G, Porcu M, Saba L. Cau R, et al. Among authors: agostinetto e. Int J Cancer. 2022 Dec 1;151(11):1860-1873. doi: 10.1002/ijc.34169. Epub 2022 Jul 25. Int J Cancer. 2022. PMID: 35730658 Free article. Review.

3

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Agostinetto E, Eiger D, Punie K, de Azambuja E. Agostinetto E, et al. Curr Oncol Rep. 2021 Mar 24;23(5):57. doi: 10.1007/s11912-021-01038-6. Curr Oncol Rep. 2021. PMID: 33763756 Review.

4

Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets.

Zambelli A, Sgarra R, De Sanctis R, Agostinetto E, Santoro A, Manfioletti G. Zambelli A, et al. Among authors: agostinetto e. Expert Opin Ther Targets. 2022 Jun;26(6):557-573. doi: 10.1080/14728222.2022.2084380. Epub 2022 Jun 8. Expert Opin Ther Targets. 2022. PMID: 35638300 Free article. Review.

5

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada AH, Santoro A, Piccart-Gebhart M, de Azambuja E. Agostinetto E, et al. Eur J Cancer. 2021 May;148:76-91. doi: 10.1016/j.ejca.2021.01.043. Epub 2021 Mar 16. Eur J Cancer. 2021. PMID: 33740500

6

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.

Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, Partridge AH, Lambertini M. Franzoi MA, et al. Among authors: agostinetto e. Lancet Oncol. 2021 Jul;22(7):e303-e313. doi: 10.1016/S1470-2045(20)30666-5. Epub 2021 Apr 20. Lancet Oncol. 2021. PMID: 33891888 Review.

7

Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Agostinetto E, Ceppi M, Bruzzone M, Lambertini M, de Azambuja E. Agostinetto E, et al. Eur J Cancer. 2021 Sep;155:303-306. doi: 10.1016/j.ejca.2021.06.042. Epub 2021 Aug 5. Eur J Cancer. 2021. PMID: 34366207 No abstract available.

8

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer.

Jacobs F, Agostinetto E, Miggiano C, De Sanctis R, Zambelli A, Santoro A. Jacobs F, et al. Among authors: agostinetto e. Cancers (Basel). 2023 May 26;15(11):2933. doi: 10.3390/cancers15112933. Cancers (Basel). 2023. PMID: 37296893 Free PMC article. Review.

9

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E. Agostinetto E, et al. Eur J Clin Invest. 2021 Jul;51(7):e13535. doi: 10.1111/eci.13535. Epub 2021 Mar 16. Eur J Clin Invest. 2021. PMID: 33662161 Review.

10

VISTA: A Promising Target for Cancer Immunotherapy?

Tagliamento M, Agostinetto E, Borea R, Brandão M, Poggio F, Addeo A, Lambertini M. Tagliamento M, et al. Among authors: agostinetto e. Immunotargets Ther. 2021 Jun 22;10:185-200. doi: 10.2147/ITT.S260429. eCollection 2021. Immunotargets Ther. 2021. PMID: 34189130 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page